Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London
Supernus (SUPN) Stock Still Looks Undervalued As Its 127% 5 Year Run Continues
B of A Securities Initiates Coverage On Supernus with Buy Rating, Announces Price Target of $47
Piper Sandler Reinstates Overweight on Supernus, Announces $47 Price Target
Indivior to Report Third Quarter 2026 Financial Results
Indivior: Sublocade Growth And Improving Profitability Create Upside Potential
Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend
Indivior Pharmaceuticals Inc. (INDV) Loses 12.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
3 Reasons Why Growth Investors Shouldn't Overlook Indivior Pharmaceuticals Inc. (INDV)
Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Cost Reset Plan
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
Should Investors Buy INDV as Sublocade Growth Meets Rising Risks?
Indivior Q2 2026 Earnings Call: Complete Transcript
Is Indivior Pharmaceuticals Inc. (INDV) a Solid Growth Stock? 3 Reasons to Think "Yes"
Barclays Maintains Overweight on Indivior Pharmaceuticals, Lowers Price Target to $43
INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook
Indivior Pharmaceuticals Inc. (INDV) Q2 Earnings and Revenues Beat Estimates
Supernus Pharmaceuticals, Indivior Pharmaceuticals to Merge in All-Stock Deal
Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.